| Literature DB >> 29328390 |
Tianlong Liu1, Minna Liu2, Peijin Shang1, Xin Jin1, Wenxing Liu1, Yikai Zhang3, Xinfang Li4, Yi Ding1, Yuwen Li1, Aidong Wen1.
Abstract
Hypertensive nephrosclerosis (HNS) is a major risk factor for end-stage renal disease. However, the underlying pathogenesis of HNS remains to be fully determined. The gene expression profile of GSE20602, which consists of 14 glomeruli samples from patients with HNS and 4 normal glomeruli control samples, was obtained from the Gene Expression Omnibus database. Gene ontology (GO) and pathway enrichment analyses were performed in order to investigate the functions and pathways of differentially expressed genes (DEGs). Pathway relation and co‑expression networks were constructed in order to identify key genes and signaling pathways involved in HNS. In total, 483 DEGs were identified to be associated with HNS, including 302 upregulated genes and 181 downregulated genes. Furthermore, GO analysis revealed that DEGs were significantly enriched in the small molecule metabolic process. In addition, pathway analysis also revealed that DEGs were predominantly involved in metabolic pathways. The tricarboxylic acid (TCA) cycle was identified as the hub pathway in the pathway relation network, whereas the sorbitol dehydrogenase (SORD) and cubulin (CUBN) genes were revealed to be the hub genes in the co‑expression network. The present study revealed that the SORD, CUBN and albumin genes as well as the TCA cycle and metabolic pathways are involved in the pathogenesis of HNS. The results of the present study may contribute to the determination of the molecular mechanisms underlying HNS, and provide insight into the exploration of novel targets for the diagnosis and treatment of HNS.Entities:
Mesh:
Year: 2018 PMID: 29328390 PMCID: PMC5802219 DOI: 10.3892/mmr.2018.8405
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Characteristics of patients with HNS (n=14) and controls (n=4). Data are presented as mean ± standard deviation.
| Category | HNS | Control |
|---|---|---|
| Gender (male/female/NA) | 11/3/0 | 0/2/2 |
| Age (years) | 58±12 | 65±9 |
| BP systolic (mmHg) | 143±18 | NA |
| BP diastolic (mmHg) | 86±13 | NA |
| Creatinine (mg/dl) | 2.3±1.7 | 1.0±0 |
| Estimated glomerular filtration rate (ml/min) | 42±24 | 59±1 |
| Proteinuria (g/24 h) | 1.6±1.7 | 0 |
BP, blood pressure; NA, not applicable; HNS, hypertensive nephrosclerosis.
Figure 1.DEGs between HNS and control samples. (A) Heat map of the DEGs, red indicates upregulated genes and green indicates downregulated genes. (B) Volcano plot of the DEGs (Yellow indicates DEGs with |log2 fold-change|>1 and false discovery rate <0.05. Blue indicates non-DEGs). HNS, hypertensive nephrosclerosis; DEG, differentially expressed genes.
Top 10 differentially expressed genes associated with hypertensive nephrosclerosis.
| Gene symbol | Gene description | Fold-change | P-value | False discovery rate |
|---|---|---|---|---|
| Albumin | 9.74 | 1.42×10−3 | 1.24×10−3 | |
| DEAD-box helicase 3, Y-linked | −9.14 | 2.18×10−2 | 2.11×10−2 | |
| Early growth response 1 | 6.78 | 4.60×10−5 | 0 | |
| FBJ murine osteosarcoma viral oncogene homolog | 6.06 | 1.90×10−4 | 0 | |
| 4-hydroxyphenylpyruvate dioxygenase | 6.04 | 3.95×10−3 | 1.83×10−3 | |
| Ribosomal protein S4, Y-linked 1 | −5.92 | 3.23×10−2 | 3.17×10−2 | |
| Amiloride binding protein 1 (amine oxidase (copper-containing)) | 5.62 | 8.38×10−3 | 5.04×10−3 | |
| Cytochrome P450, family 4, subfamily A, polypeptide 11 | 5.48 | 2.18×10−3 | 1.24×10−3 | |
| Aldolase B, fructose-bisphosphate | 5.37 | 7.44×10−3 | 5.04×10−3 | |
| γ-butyrobetaine hydroxylase 1 | 5.05 | 4.00×10−3 | 3.23×10−3 |
Top 10 significant gene ontology terms of differentially expressed genes associated with hypertensive nephrosclerosis.
| Gene ontology name | Differentially expressed genes | P-value | False discovery rate |
|---|---|---|---|
| Small molecule metabolic process | 76 | 1.10×10−37 | 2.14×10−34 |
| Cellular nitrogen compound metabolic process | 21 | 6.42×10−17 | 6.25×10−14 |
| Transmembrane transport | 30 | 4.48×10−15 | 2.91×10−12 |
| Xenobiotic metabolic process | 16 | 2.80×10−13 | 1.36×10−10 |
| Response to drug | 20 | 1.72×10−12 | 6.71×10−10 |
| Cellular response to calcium ion | 9 | 7.68×10−12 | 2.49×10−9 |
| Platelet degranulation | 12 | 1.68×10−11 | 4.67×10−9 |
| Platelet activation | 16 | 1.16×10−10 | 2.82×10−8 |
| Steroid metabolic process | 10 | 1.36×10−10 | 2.95×10−8 |
| Gluconeogenesis | 9 | 3.41×10−10 | 6.64×10−8 |
Figure 2.Histogram of the top 10 significant (A) GO categories and (B) pathways of differentially expressed genes associated with hypertensive nephrosclerosis. GO, gene ontology; PPAR, peroxisome proliferator-activated receptor.
Top 10 significant pathways of differentially expressed genes associated with hypertensive nephrosclerosis.
| Pathway name | Differentially expressed genes | P-value | False detection rate |
|---|---|---|---|
| Metabolic pathways | 65 | 1.32×10−31 | 2.69×10−29 |
| PPAR signaling pathway | 13 | 1.29×10−13 | 1.32×10−11 |
| Protein digestion and absorption | 12 | 4.61×10−11 | 3.13×10−9 |
| Cell adhesion molecules | 14 | 1.27×10−10 | 6.50×10−9 |
| Arginine and proline metabolism | 10 | 1.64×10−10 | 6.68×10−9 |
| Drug metabolism-cytochrome P450 | 10 | 2.38×10−9 | 8.10×10−8 |
| Glycine, serine and threonine metabolism | 7 | 6.81×10−8 | 1.98×10−6 |
| Proximal tubule bicarbonate reclamation | 6 | 8.44×10−8 | 2.15×10−6 |
| Tryptophan metabolism | 7 | 1.20×10−7 | 2.73×10−6 |
| Carbohydrate digestion and absorption | 7 | 2.82×10−7 | 5.76×10−6 |
Figure 3.Relationship network of significant pathways associated with hypertensive nephrosclerosis. Nodes represent pathways. The size of the nodes represents the associated degree value. Lines with arrows represent interactions between pathways, whereas the pathways with arrow tails regulate pathways with the associated arrow's head. Red nodes represent upregulated pathways, blue nodes represent downregulated pathways, and yellow nodes indicate that there were genes associated with the pathway that were both up and downregulated. PPAR, peroxisome proliferator-activated receptor; MAPK, mitogen-activated protein kinase; ECM, extracellular matrix.
Top 10 key pathways according to the degree.
| Pathway name | Out degree | In degree | Total degree |
|---|---|---|---|
| Tricarboxylic acid cycle | 6 | 13 | 19 |
| Glycolysis/gluconeogenesis | 4 | 12 | 16 |
| MAPK signaling pathway | 0 | 16 | 16 |
| Pyruvate metabolism | 7 | 8 | 15 |
| Pathways in cancer | 12 | 0 | 12 |
| Propanoate metabolism | 6 | 5 | 11 |
| Cell adhesion molecules | 4 | 7 | 11 |
| T cell receptor signaling pathway | 3 | 8 | 11 |
| Ascorbate and aldarate metabolism | 4 | 4 | 8 |
| Synthesis and degradation of ketone bodies | 4 | 4 | 8 |
Out degree, number of downstream pathways; In degree, number of upstream pathways; Total degree, sum of out degree and in degree values.
Figure 4.Gene co-expression network of differentially expressed genes associated with hypertensive nephrosclerosis. Nodes denote genes; edges represent gene-gene interactions and the size of the nodes represents the associated degree value.
Top 10 key genes according to the degree value.
| Gene | Description | Degree |
|---|---|---|
| Sorbitol dehydrogenase | 22 | |
| Glycine-N-acyltransferase | 21 | |
| Cubilin (intrinsic factor-cobalamin receptor) | 15 | |
| Pipecolic acid oxidase | 14 | |
| Ureidopropionase, β | 14 | |
| 4-hydroxyphenylpyruvate dioxygenase | 14 | |
| Dihydropyrimidinase | 14 | |
| Solute carrier family 7 member 9 | 14 | |
| Kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) | 13 | |
| Serine hydroxymethyltransferase 1 (soluble) | 13 |
Degree, number of the associated gene interactions with the key gene in the network.